Cite
Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study.
MLA
Maza-Solano, Juan, et al. “Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study.” Journal of Clinical Medicine, vol. 11, no. 23, Dec. 2022, p. 7056. EBSCOhost, https://doi.org/10.3390/jcm11237056.
APA
Maza-Solano, J., Calvo-Henríquez, C., Alobid, I., Álvarez-Cendrero, M., Palomares, Ó., Moreno-Luna, R., Santos-Perez, J., González-García, J., & Sánchez-Gómez, S. (2022). Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study. Journal of Clinical Medicine, 11(23), 7056. https://doi.org/10.3390/jcm11237056
Chicago
Maza-Solano, Juan, Christian Calvo-Henríquez, Isam Alobid, Marta Álvarez-Cendrero, Óscar Palomares, Ramón Moreno-Luna, Jaime Santos-Perez, Jaime González-García, and Serafín Sánchez-Gómez. 2022. “Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study.” Journal of Clinical Medicine 11 (23): 7056. doi:10.3390/jcm11237056.